GPL
NEUTRALGraft Polymer Rebrands as Solvonis Therapeutics to Focus on Mental Health
Innovative biotech company pivots focus to mental health therapeutics
GPL
0.00%
Market Cap
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
p - p
52 Week Range
N/AppN/Ap
p
Upcoming Events
15 June 2025
Long Stop Date for completion of the proposed acquisition
High Impact Event
No data available for this timeframe
GPL
GOODGraft Polymer Showcases Mental Health Expertise in Proactive Interviews
Innovative biotechnology company developing mental health treatments showcases expertise in Proactive Investor interviews.
GPL
GOODGraft Polymer Expands into Mental Health with Awakn Life Sciences Acquisition
Biotechnology company Graft Polymer to acquire Awakn Life Sciences, expanding into mental health and addiction treatment.
GPL
GOODGraft Polymer Announces Promising Results in Aminoindane NCE Programme
Promising results from a pre-clinical study on a novel mental health treatment programme, with potential to address a large unmet need.
GPL
GOODGraft Polymer Announces Proposed Name Change to Solvonis Therapeutics, Continued Progress in Awakn Collaboration
Innovative biotech company pivots towards therapeutics, progresses key collaboration
GPL
GOODGraft Polymer Announces Research Agreement with University of Nottingham
Biotechnology company Graft Polymer announces research agreement with University of Nottingham to evaluate potential of its drug candidates for mental health disorders.
GPL
GOODGraft Polymer Appoints Industry Leader as New Chairman
Innovative biotechnology company appoints new Chairman to lead its strategic initiatives.
GPL
GOODGraft Polymer Appoints Biotech Veteran Dennis Purcell as New Chairman
Biotechnology company Graft Polymer appoints industry veteran as new Chairman, signaling potential growth ahead.
GPL
VERY BADGraft Polymer Faces Mounting Losses and Cash Crunch
Struggling specialty industrial machinery company faces severe financial challenges